Glaxo Smith Kline (GSK) acquiring complete control of from its Joint Venture with Novartis of the Consumer Health Care Assets for $13 Billion.GSK is acquiring 36.5% stake of the Joint Venture held by Novartis, and now GSK will have 100% control of this Consumer Health Care Unit.

Glaxo Smith Kline (GSK) has major ambitions for growing in the consumer health care market.Note the URL for GSK Press Release from March 27, 2018, posted below:

https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/(Links to an external site.)

GSK's goal is to reach operating margins in the mid - 20's for its Consumer Health Care Business by the Year 2022.

GSK has a major presence and growth ambitions in India, and it is also listed there on several stock exchanges.

GSK's primary stock listing is on the London Stock Exchange, and it is also listed on the NYSE as "GSK."It closed on Friday, Sept. 20th, 2019 at $4163.Its EPS for TTM (Trailing Twelve Months) is $0.99, and its Price / Earnings Multiple is 41.97 X.

GSK has a Total Market Capitalization of $104.192 Billion.

What are your thoughts and assessments on this Asset Purchase?